Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Resistance to therapy caused by intragenic deletion in BRCA2


Cells with loss of BRCA2 function are defective in homologous recombination (HR) and are highly sensitive to inhibitors of poly(ADP-ribose) polymerase (PARP)1,2, which provides the basis for a new therapeutic approach. Here we show that resistance to PARP inhibition can be acquired by deletion of a mutation in BRCA2. We derived PARP-inhibitor-resistant (PIR) clones from the human CAPAN1 pancreatic cancer cell line, which carries the protein-truncating c.6174delT frameshift mutation. PIR clones could form DNA-damage-induced RAD51 nuclear foci and were able to limit genotoxin-induced genomic instability, both hallmarks of a competent HR pathway. New BRCA2 isoforms were expressed in the resistant lines as a result of intragenic deletion of the c.6174delT mutation and restoration of the open reading frame (ORF). Reconstitution of BRCA2-deficient cells with these revertant BRCA2 alleles rescued PARP inhibitor sensitivity and HR deficiency. Most of the deletions in BRCA2 were associated with small tracts of homology, and possibly arose from error-prone repair caused by BRCA2 deficiency3,4. Similar ORF-restoring mutations were present in carboplatin-resistant ovarian tumours from c.6174delT mutation carriers. These observations have implications for understanding drug resistance in BRCA mutation carriers as well as in defining functionally important domains within BRCA2.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: PIR CAPAN1 clones.
Figure 2: BRCA2 expression in PIR clones.
Figure 3: Expression of new mutant BRCA2 isoforms restores KU0058948 resistance and increases HR in BRCA2 deficient cells.
Figure 4: Identification of BRCA2 ORF-restoring mutations in carboplatin-resistant tumours in BRCA2 c.6174delT mutation carriers.

Similar content being viewed by others


  1. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005)

    Article  CAS  ADS  Google Scholar 

  2. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005)

    Article  CAS  ADS  Google Scholar 

  3. Tutt, A. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20, 4704–4716 (2001)

    Article  CAS  Google Scholar 

  4. Moynahan, M. E., Pierce, A. J. & Jasin, M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol. Cell 7, 263–272 (2001)

    Article  CAS  Google Scholar 

  5. Domchek, S. M. & Weber, B. L. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25, 5825–5831 (2006)

    Article  CAS  Google Scholar 

  6. Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864–5874 (2006)

    Article  CAS  Google Scholar 

  7. Davies, O. R. & Pellegrini, L. Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat. Struct. Mol. Biol. 14, 475–483 (2007)

    Article  Google Scholar 

  8. Esashi, F., Galkin, V. E., Yu, X., Egelman, E. H. & West, S. C. Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat. Struct. Mol. Biol. 14, 468–474 (2007)

    Article  CAS  Google Scholar 

  9. Ratnam, K. & Low, J. A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 13, 1383–1388 (2007)

    Article  CAS  Google Scholar 

  10. Goggins, M. et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56, 5360–5364 (1996)

    CAS  PubMed  Google Scholar 

  11. Yang, H. et al. BRCA2 function in DNA binding and recombination from a BRCA2–DSS1-ssDNA structure. Science 297, 1837–1848 (2002)

    Article  CAS  ADS  Google Scholar 

  12. Spain, B. H., Larson, C. J., Shihabuddin, L. S., Gage, F. H. & Verma, I. M. Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc. Natl Acad. Sci. USA 96, 13920–13925 (1999)

    Article  CAS  ADS  Google Scholar 

  13. Abaji, C., Cousineau, I. & Belmaaza, A. BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis. Cancer Res. 65, 4117–4125 (2005)

    Article  CAS  Google Scholar 

  14. McCabe, N. et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly(ADP-ribose) polymerase: an issue of potency. Cancer Biol. Ther. 4, 934–936 (2005)

    Article  CAS  Google Scholar 

  15. Tutt, A. N. et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 139–148 (2005)

    Article  CAS  Google Scholar 

  16. Furuta, T. et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 278, 20303–20312 (2003)

    Article  CAS  Google Scholar 

  17. Weinstock, D. M., Elliott, B. & Jasin, M. A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. Blood 107, 777–780 (2006)

    Article  CAS  Google Scholar 

  18. Saeki, H. et al. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc. Natl Acad. Sci. USA 103, 8768–8773 (2006)

    Article  CAS  ADS  Google Scholar 

  19. Cass, I. et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97, 2187–2195 (2003)

    Article  CAS  Google Scholar 

  20. Pal, T., Permuth-Wey, J., Kapoor, R., Cantor, A. & Sutphen, R. Improved survival in BRCA2 carriers with ovarian cancer. Fam. Cancer 6, 113–119 (2007)

    Article  CAS  Google Scholar 

  21. Wang, D. & Lippard, S. J. Cellular processing of platinum anticancer drugs. Nature Rev. Drug Discov. 4, 307–320 (2005)

    Article  CAS  Google Scholar 

  22. Hirschhorn, R. In vivo reversion to normal of inherited mutations in humans. J. Med. Genet. 40, 721–728 (2003)

    Article  CAS  Google Scholar 

  23. Xia, B. et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nature Genet. 39, 159–161 (2007)

    Article  CAS  Google Scholar 

  24. Daniels, M. J., Wang, Y., Lee, M. & Venkitaraman, A. R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306, 876–879 (2004)

    Article  CAS  ADS  Google Scholar 

  25. Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocols 1, 1112–1116 (2006)

    Article  CAS  Google Scholar 

  26. Gudmundsdottir, K., Lord, C. J., Witt, E., Tutt, A. N. & Ashworth, A. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep. 5, 989–993 (2004)

    Article  CAS  Google Scholar 

  27. Reis-Filho, J. S. et al. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J. Pathol. 207, 1–13 (2005)

    Article  CAS  Google Scholar 

  28. Poch, G. & Pancheva, S. N. Calculating slope and ED50 of additive dose–response curves, and application of these tabulated parameter values. J. Pharmacol. Toxicol. Methods 33, 137–145 (1995)

    Article  CAS  Google Scholar 

  29. Bertwistle, D. et al. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res. 57, 5485–5488 (1997)

    CAS  PubMed  Google Scholar 

  30. Lambros, M. B. et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab. Invest. 86, 398–408 (2006)

    Article  CAS  Google Scholar 

Download references


We thank M. Jasin and N. Siaud for providing the VC8-DR-GFP cell line, G. Smith and N. Martin for the provision of KU0058948, and S. Swift, A. Smith and K. Savage for technical support. This work was funded by Breakthrough Breast Cancer and Cancer Research UK. S.L.E. is a C. J. Martin Fellow and is supported by the National Health and Medical Research Council of Australia.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Alan Ashworth.

Ethics declarations

Competing interests

Authors A.A. and C.J.L. are inventors on patents held jointly with KuDOS/AstraZeneca relating to the use of PARP inhibitors. They may benefit financially from these under the Institute of Cancer Research’s Rewards to Inventors scheme.

Supplementary information

Supplementary Information

The file contains Supplementary Figures S1- S3 with Legends and additional references. (PDF 502 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edwards, S., Brough, R., Lord, C. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111–1115 (2008).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing